These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 576725)

  • 61. Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly.
    Giustina A; Doga M; Bussi AR; Licini M; Schettino M
    Acta Endocrinol (Copenh); 1993 Feb; 128(2):131-5. PubMed ID: 7680832
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term treatment of acromegaly with lisuride: differences of effect on growth hormone and somatomedin.
    Marek J; Srámková J; Schüllerová M; Stĕpán J; Schreiberová O
    Endokrinologie; 1981 Dec; 78(2-3):175-85. PubMed ID: 7037372
    [No Abstract]   [Full Text] [Related]  

  • 63. Bromocriptine suppression of plasma growth hormone in acromegaly.
    Dunn PJ; Donald RA; Espiner EA
    Clin Endocrinol (Oxf); 1977 Oct; 7(4):273-81. PubMed ID: 336245
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states.
    Verde G; Chiodini PG; Liuzzi A; Cozzi R; Favales F; Botalla L; Spelta B; Dalla Bonzana D; Rainer E; Horowski R
    J Endocrinol Invest; 1980; 3(4):405-14. PubMed ID: 6782153
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Treatment of hyperprolactinemia and acromegaly with lisuride].
    Berezin M; Elchalal U; Olchovsky D
    Harefuah; 1989 Jun; 116(12):634-7. PubMed ID: 2792946
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Changes of molecular forms of growth hormone in bromocriptine treated acromegaly in relation to changes of somatomedin-C and clinical response.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1985 Feb; 108(2):145-50. PubMed ID: 4038567
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of the acute administration of haloperidol and pimozide on plasma GH levels in acromegaly.
    Carmina E; Lo Coco R; Lanzara P; Jannì A
    Acta Endocrinol (Copenh); 1979 Aug; 91(4):609-15. PubMed ID: 115193
    [TBL] [Abstract][Full Text] [Related]  

  • 69. No effect of treatment with sodium valproate on plasma growth hormone in bromocriptine unresponsive acromegaly.
    Nortier JW; Croughs RJ; Schwarz F; Thijssen JH
    Acta Endocrinol (Copenh); 1986 Feb; 111(2):162-4. PubMed ID: 3082095
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion.
    Rau H; Althoff PH; Schmidt K; Badenhoop K; Usadel KH
    Clin Investig; 1993 May; 71(5):372-8. PubMed ID: 8508007
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of tamoxifen on GH and PRL secretion by human pituitary tumors.
    Lamberts SW; de Quijada M; Klijn JG
    J Endocrinol Invest; 1980; 3(4):343-7. PubMed ID: 7204884
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Acromegaly--results of long term treatment with bromocriptine.
    Besser GM; Wass JA; Thorner MO
    Acta Endocrinol Suppl (Copenh); 1978; 216():187-98. PubMed ID: 347861
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitary testing: a review of the literature on 36 cases of pituitary carcinoma.
    Mountcastle RB; Roof BS; Mayfield RK; Mordes DB; Sagel J; Biggs PJ; Rawe SE
    Am J Med Sci; 1989 Aug; 298(2):109-18. PubMed ID: 2669475
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Somatostatin analog treatment of acromegaly: new aspects.
    Lamberts SW; del Pozo E
    Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Longterm pergolide treatment of acromegaly.
    Kendall-Taylor P; Upstill-Goddard G; Cook D
    Clin Endocrinol (Oxf); 1983 Dec; 19(6):711-9. PubMed ID: 6652932
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin.
    Werner S; Hall K; Sjöberg HE
    Acta Endocrinol Suppl (Copenh); 1978; 216():199-206. PubMed ID: 347862
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
    Gasińska T; Nowak S
    Endokrynol Pol; 1993; 44(4):455-65. PubMed ID: 8055814
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Somatostatin analogue (SMS 201-995) in resistant acromegaly: a preliminary report.
    Atkinson AB; McKnight JA; McCance DR; Bell PM
    Horm Res; 1990; 33 Suppl 1():7-11; discussion 11-2. PubMed ID: 2358295
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CV 205-502 in acromegaly.
    Chiodini PG; Attanasio R; Cozzi R; Dallabonzana D; Oppizzi G; Orlandi P; Strada S; Liuzzi A
    Acta Endocrinol (Copenh); 1993 May; 128(5):389-93. PubMed ID: 8100375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.